

# HTLV-1 Infection as a Serious Health Issue among Iranian Multi-Transfused Patients: Evidence from a Systematic Review and Meta-Analysis

Dayyani M<sup>1,2</sup>, Hedayati-Moghaddam MR<sup>1\*</sup>, Amini AR<sup>3</sup>

1. Research Centre for HIV/AIDS, HTLV and Viral Hepatitis, Iranian Academic Centre for Education, Culture and Research (ACECR), Mashhad Branch, Mashhad, Iran.

2. Student Research Committee, Mashhad University of Medical Sciences, Mashhad, Iran.

3. Student Research Committee, Faculty of Health, Mashhad University of Medical Sciences, Mashhad, Iran.

\*Corresponding Author: Hedayati-Moghaddam MR, Email: drhedayati@acecr.ac.ir

Submitted: 01-07-2014, Accepted: 12-10-2014

## Abstract

**Background:** A high prevalence of human T-cell lymphotropic virus type 1 (HTLV-1) infection among general population in the northeast of Iran has been reported. Multi-transfused patients are known as 'at-risk' group for the infection. This systematic review and meta-analysis was conducted to estimate the prevalence of HTLV-1 infection among Iranian multi-transfused patients.

**Materials and Methods:** Electronic databases including PubMed, Scopus, ISI, Google Scholar, ProQuest, ScienceDirect, IMEMR, IranMedex, Magiran, IranDoc, ISNet, RICEST and SID as well as grey literatures in both English and Persian were searched up to December 2013 and the related studies were critically appraised. Data were analyzed with R software version 3.1.2.

**Results:** A total of 551 non-duplicate and non-overlapping citations were found in primary search, of which 18 documents surveyed HTLV-1 infection prevalence among Iranian multi-transfused patients. Six non-duplicate and non-overlapping studies were added from grey literatures search. Out of these 24 documents, 16 studies conducted among 3922 patients from 14 provinces met the inclusion criteria. The HTLV-1 infection prevalence varied considerably and the highest prevalence (14.4%) was reported among hemodialysis patients from Neyshabour, Northeastern Iran. Overall estimation of HTLV-1 prevalence was 3.2% (95%CI: 2.2-4.8). The HTLV-1 infection prevalence among patients with thalassemia and hemodialysis were 4.1% (95%CI: 3.4-4.9) and 2.9% (95%CI: 0.96-8.3), respectively.

**Conclusion:** HTLV-1 infection prevalence among patients with frequent transfusions in Iran varies greatly in different parts of the country, but it is endemic in nearly all provinces. Therefore, the infection should be considered as a serious health problem in the whole country.

**Keywords:** HTLV-1 infections, multi-transfused patients, review, meta-analysis, Iran.

## Introduction

Human T lymphotropic virus type 1 (HTLV-1) is a single stranded RNA retrovirus that expresses special proteins with oncogenic potential. For the first time, HTLV-1 was identified in 1980 in a patient with cutaneous T cell lymphoma and was also recognized in adult T cell leukemia (ATL) patients<sup>1</sup>. It is estimated that approximately 15 to 20 million people are infected with the virus worldwide<sup>2</sup>. HTLV-1 infection is endemic in Southwestern Japan,

sub-Saharan Africa and the Caribbean region and is also frequently found in several countries in South America<sup>2</sup>, some Islands of Oceania<sup>3</sup>, and Northeastern Iran<sup>4</sup>.

Although there is no symptoms showing the infection in most infected people, association of the virus with exceptionally severe diseases such as ATL and HTLV-1-associated myelopathy/tropical spastic paraparesis have been proven<sup>5</sup>. Moreover, HTLV-1

is less commonly associated with a wide spectrum of inflammatory conditions and tumors such as HTLV-1 associated uveitis<sup>6</sup>, chronic inflammatory arthropathy<sup>7</sup>, dermatitis, polymyositis, lymphadenitis, Sjogren's syndrome<sup>2</sup>, non-Hodgkin's T cell lymphoma<sup>8</sup>, T-prolymphocytic leukemia, small cell carcinoma, large granular lymphocytic leukemia<sup>9</sup> and B cell chronic lymphocytic leukemia<sup>10</sup>.

HTLV-1 seropositivity can occur through the several routes which include mother to child mainly through breastfeeding; sexual intercourse; and parenteral transmission by transfusion of infected blood products or sharing of needles and syringes<sup>11</sup>. Almost 12% of HTLV infections occur by blood transfusion and contrary to HIV-1, whole cell transfusion is needed for transmission of the virus<sup>12,13</sup> with a seroconversion rate of almost 50%. Nevertheless, the risk of transmission decreases noticeably if the blood units are stored for more than one week before transfusion<sup>14</sup>.

Patients with thalassemia, hemophilia and those undergoing hemodialysis are more at risk of HTLV-1 infection due to their need for frequent transfusions<sup>15-17</sup>. A study by Barton et al.<sup>18</sup>, showed a higher seroprevalence of anti-HTLV-1 among Jamaican hemodialysis patients (9.5%) compared to an age- and gender-matched control group.

HTLV-1 infection is nearly endemic in some cities of Razavi Khorasan province, Northeast of Iran<sup>4,19,20</sup>. Furthermore, some studies have demonstrated a noticeable prevalence of the infection in multi-transfused patients around the country. Recently, Bidkhori et al.<sup>21</sup>, reported a prevalence of HTLV- I infection as high as 14.6% among hemodialysis patients in Neyshabour, Northeastern Iran.

To our knowledge, there is no overall estimation of HTLV-1 infection prevalence among high risk groups in Iran. This systematic review and meta-analysis was conducted to estimate of the prevalence of this infection among Iranian patients with frequent transfusions.

## Materials and Methods

### Study Question

Desired outcome was the presence of HTLV-1 antibody in blood samples of the Iranian thalassemic, hemophilic and hemodialysis patients which was confirmed by western blot or PCR, until December 2013.

### Search Strategy

The following phrase was used anywhere in the text for searching English electronic databases and websites: "HTLV AND Iran AND (multitransfused OR polytransfused OR frequent transfusion OR thalassaemia OR thalassemia OR thalassaemic OR thalassemic OR haemophilia OR haemophilic OR hemophilia OR hemophilic OR haemodialysis OR hemodialysis)". "HTLV" and Persian corresponding substitutes for "multitransfused", "thalassaemia", "hemophilia" and "hemodialysis" in all fields, were also used for searching national databases.

### Electronic Databases

Six electronic bibliographic databases and publishers of the health and biological sciences including PubMed, Scopus, Web of Knowledge (ISI), Google Scholar, Proquest and Sciencedirect were searched. Moreover, six Iranian literature databases were investigated. These included: Iranian Research Institute for Information Science and Technology (IranDoc), Iranian Database of Medical Sciences Papers (IranMedex), Iranian Database of Publication (Magiran), National Management System for Science and Technology Information (ISNet), the Regional Information Centre for Science & Technology (RICeST), and Scientific Information Database (SID).

### Gray Literature Search

All Iranian Medical Universities' websites, official websites of Center for Disease Control of the Iranian Ministry of Health and the Iranian Blood Transfusion Organization, available abstract books as well as some Iranian databases such as IranDoc, RICeST, ISNet, IranMedex and SID were searched to obtain relevant research projects, dissertations, scientific reports of congresses and organization reports.

### Critical Appraisal and Selection of Studies

To assess the eligibility of studies, all titles and abstracts were screened and possibly pertinent citations were reviewed completely. The inclusion criteria were all cross-sectional surveys with any sample size that reported prevalence of HTLV-1 infection in thalassemic, hemophilic and hemodialysis patients using valid measurement methods and confirmatory tests such as western blot and/ or PCR, in both English and Persian languages.

## Data Extraction

The selected and included documents were reviewed and the findings were extracted to a table. The extracted data comprised first author, year of the conduction of the study, name of province/city, disease of the study group, sample size, kits and methods used for HTLV antibody detection, confirmatory tests, mean and standard deviation of subjects' age, percentage of male subjects and total HTLV-1 point prevalence.

## Statistical Analysis

The total and sex-related point prevalence of HTLV-1 infection was recalculated according to the number of the infected cases and total observations reported in each study and if the number of cases was not stated, the reported prevalence was assumed as a desired amount. Binomial 95% confidence interval for point prevalence was computed using Epi Info software version 6.04d (CDC, Atlanta, GA).

Meta-analysis was performed using R software version 3.1.2 (Free Software Foundation Inc., Boston, MA), by random or fixed effect model based on the results of heterogeneity test (Cochrane Q) with significance set at 0.05.

## Results


### Search Result

Among a total number of 662 citations found in the electronic search, 551 were non-duplicate and non-overlapping, of which 18 relevant studies had surveyed seroprevalence of HTLV-1 in Iranian multi-transfused patients (Figure 1). Three studies<sup>22-24</sup> were excluded due to lack of reliable confirmatory tests in their diagnostic protocols and 15 studies were included in the analysis<sup>25-39</sup>.

In gray literature search, 25 surveys including 11 theses, 8 research reports, and 6 published conference abstracts were found. Six non-duplicate and non-overlapping studies were chosen, of which one eligible document<sup>21</sup> was included in the analysis. Among five remaining surveys; two were excluded due to lack of reliable confirmatory tests, one was excluded because of some methodological errors, and two were not accessible in abstract/ full text.

### Studies


The total number of patients participating in these 16 studies was 3922; ranging from 80 to 868 in each study. Selected surveys have been implemented from 1994 to 2013 on patients




**Figure 1:** Flowchart of searches for selection of surveys on HTLV-1 infection prevalence among Iranian multi-transfused patients.

Table 1: Selected studies included in the analysis.


First author	Year of study	Province	Population	Age (year)	Male Gender (%)	Sample size	Prevalence (%)	Method of detection	Kit
Karimi, A	2005	Charmahal-va-Baktiari	Thalassemia	1-45	62	250	6.8	ELISA, WB	Organon
			Hemodialysis	18-90	58	107	6.54		
			Total: 6.72						
Sotoodeh, M Abedi, F	1994	Fars	Thalassemia	6-24	----	357	2.5	ELISA, WB	----
	2008	Hormozgan	Thalassemia	9-79	53.3	163	3.06	ELISA, WB,	Gen labs
			Hemophilia			40	0	PCR	Gen labs
			Hemodialysis			7	0	Total: 2.38	
	Moradi, A	2005	Golestan	Thalassemia	14.1±6.5	51.4	210	4.42	ELISA, WB
Pourkarim, MR	2005	Bushehr	Thalassemia	----	----	455	3.08	ELISA, WB	Gen labs
			Hemophilia	----	----	86	0		Organon
			Hemodialysis	----	----	101	0		Gen labs
			Total: 2.18						
Ghaffari, J	2009	Mazandaran	Thalassemia	21.5±6.6	47.6	642	1.39	ELISA, PCR	DiaPro
Ghaffari, J	2011	Mazandaran	Hemodialysis	59.1±14.7	50	288	0.63	ELISA, WB	Qiagen
Ghadiri, K	2010	Kermanshah	Thalassemia	16.8±6.6	55.1	116	3.45	ELISA, WB	DiaPro
Rostamzadeh	2005 -	West	Hemodialysis	<40, >70	50.5	95	1.05	ELISA, WB	Gen labs
Khameneh, Z	2006	Azarbayjan							Gen labs
Anaraki-Mohammadi,GR	2003	Tehran	Thalassemia	18.1±1	57.7	175	6.29	ELISA, WB	Gen labs
Moradi, A	2002	Sistan and Balouchestan	Thalassemia	8.8±4.5	57.9	190	1.58	ELISA, WB	Gen labs
Rezvan, H	1996	Tehran	Thalassemia	----	----	632	4.59	ELISA, WB	Biorad
			Hemophilia			236	2.97		----
						Total: 4.15			Organon
Ziaee, M	2007	South khorasan	Hemophilia	21.3±12.1	96.3	868	1.25	ELISA, RIBA	Genlabs
Bidkhor, HR	2012	Razavi Khorasan	Hemodialysis	53.4±17.8	54.9	139	14.39	ELISA, WB	DiaPro
Ardalan, N	2010	Kordestan	Thalassemia	13.3±?	57	46	2.17	ELISA, WB	DiaPro
			Hemodialysis	45.1±?	54	65	0		
			Total: 0.9						
Mortezaee, Z	2007	Isfahan	Thalassemia	1-49	58.7	111	3.33	ELISA, WB	DiaPro
						150			Gen labs




**Figure 2:** Geographical distribution of HTLV-1 infection among multi-transfused patients in different provinces of Iran.



**Figure 3:** Forest plot of surveys on prevalence of HTLV-I infection among Iranian multi-transfused patients.



**Figure 4:** Forest plot of surveys on prevalence of HTLV-I infection among patients with thalassemia.



**Figure 5:** Forest plot of surveys on prevalence of HTLV-I infection among patients undergoing hemodialysis.

with thalassemia, hemophilia and hemodialysis (Table1.) Age of the participants was mentioned just in twelve studies and based on the studies that determined sex distribution, in average 56.3% of patients were male.

Fifteen studies had used different ELISA kits such as Diapro (seven studies), Organon (four studies), Genlab (three studies) and Bio-rad (one study) for primary screening. Three types of immunoblot kits including Genlab, DB Blot and INNO-LIA were applied by 14 studies and polymerase chain reaction (PCR) technique were used by two surveys as confirmatory tests.

### HTLV-1 infection prevalence

Geographical distribution of HTLV-1 infection in Iran is demonstrated in figure 2. The highest and the lowest prevalence rates have been reported among hemodialysis patients from Neyshabour, Northeastern Iran (14.49%) and Mazandaran province in the north of Iran (0.63%), respectively. Meta-analysis revealed that overall estimation of the HTLV-1 prevalence among patients with frequent transfusions is 3.24% (95%CI: 2.19-4.78 percent) (Figure 3). After excluding the study reporting the highest prevalence 21, analysis showed that overall estimation is 3.03% (95%CI:



2.2-4.15 percent). The corresponding forest plots for thalassemic and hemodialysis patients were separately outlined (Figures 4, 5). Based on 12 studies among thalassemic patients, the prevalence in this population was 4.09% (95%CI: 3.39-4.93%).

Moreover, a rate of 2.88% (95%CI: 0.96-8.29 percent) was achieved as overall estimation of the prevalence in hemodialysis patients.

## Discussion

Northeastern Iran is one of the known endemic areas for HTLV-1 infection<sup>4,19,20</sup>. Thalassemic, hemophilic and hemodialysis patients are considered as high risk groups for the infection because of their need for frequent transfusions. This systematic review revealed that geographical distribution of HTLV-1 infection in Iranian multi-transfused patients is different. The prevalence of the virus among multi-transfused patients in almost all of the provinces is higher than 1%, which is considered as endemic level. Remarkably, in three provinces of Razavi Khorasan, Chaharmahal-Bakhtiari and Tehran, the prevalence rate was higher than 5%. These substantial discrepancies were also observed among blood donors from different provinces of the country in our previous study<sup>40</sup>. Overall estimation of HTLV-1 prevalence rate in the whole multi-transfused patients was 3.2% (95% CI, 2.2-4.8%). This rate is nearly equal to the prevalence of infection in Neyshabour city with a rate of 3.4% (95% CI, 2.4-4.7), the utmost rate among general population in Iran<sup>41</sup>. In addition, there was a small difference in the prevalence between thalassemic and hemodialysis patients that probably can be attributed to the different procedure of transfusion and different types of blood products in these two diseases.

HTLV-1 infection rates are significantly higher among poly-transfused patients in countries with a high prevalence in the general population or blood donors. For instance, Barton et al<sup>18</sup>, have reported the prevalence of infection as high as 9.5% among hemodialysis patients in Jamaica where 6.1% of general population and 2% of blood donors have been reported to show seropositivity for the virus. On the other hand, there is no robust evidence on HTLV-1 infection among patients with frequent transfusion in countries with a low frequency of the infection in the general population or volunteers of blood donation. In a multi-center study in Italy<sup>42</sup>,

prevalence rate of the infection among 14000 blood donors from different cities of the country was 0.03%. More surprisingly, there was no report on the infection from centers of two thalassemia endemic areas and the same results were found among hemophilic and hemodialysis patients of Millan. Correspondingly, none of hemophiliacs in Italy were anti-HTLV-1/2 positive, even though, 63.1% showed reactivity for HIV antibodies<sup>43</sup>. Another study in Germany demonstrated no positive case for either HTLV-1 or HTLV-2 infection among blood donors, hemophilic patients and injection drug users<sup>44</sup>. A study on Lebanese blood donors and multi-transfused patients, reported no seroreactivity for anti-HTLV antibodies<sup>45</sup>. Similar findings have been reported in a large study on blood recipients in London where only one infected blood unit out of 5939 recipients was detected<sup>46</sup>. Similarly, the prevalence among blood donors from London was reported to be 0.005 percent<sup>46</sup>. Furthermore, a survey by Mojaat et al.<sup>47</sup>, showed that the prevalence rate of the infection among Tunisian hemodialysis patients is low (0.4%) and there was no positive sample among blood donors and thalassemic patients, however; prevalence of HBV and HCV among hemodialysis patients was 8% and 45.1%, respectively.

## Conclusion

HTLV-1 infection prevalence among patients with frequent transfusions in Iran varies greatly in different parts of the country, but it is endemic in nearly all of provinces. Therefore, the infection should be addressed as a serious health problem in the whole country.

## Acknowledgements

This study was financially supported by Deputy for Research and Technology of Iranian Academic Center for Education, Culture and Research (ACECR) (Grant number: 2200-20). We would like to thank Ms. Farzaneh Barzkar and Mr. Hamid Reza Tabrizian for their kind help in language revision.

## References

1. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. *Proc Natl Acad Sci U S A*. 1980;77(12):7415-9.
2. Proietti FA, Carneiro-Proietti AB, Catalan-Soares

- BC, Murphy EL. Global epidemiology of HTLV-I infection and associated diseases. *Oncogene*. 2005;24(39):6058-68.
3. Yanagihara R, Jenkins CL, Alexander SS, Mora CA, Garruto RM. Human T lymphotropic virus type I infection in Papua New Guinea: high prevalence among the Hagahai confirmed by western analysis. *J Infect Dis*. 1990;162(3):649-54.
  4. Rafatpanah H, Hedayati-Moghaddam MR, Fathimoghadam F, Bidkhori HR, Shamsian SK, Ahmadi S, et al. High prevalence of HTLV-I infection in Mashhad, Northeast Iran: a population-based seroepidemiology survey. *J Clin Virol*. 2011;52(3):172-6.
  5. Verdonck K, González E, Van Dooren S, Vandamme AM, Vanham G, Gotuzzo E. Human T-lymphotropic virus 1: recent knowledge about an ancient infection. *Lancet Infect Dis*. 2007;7(4):266-81.
  6. Mochizuki M, Yamaguchi K, Takatsuki K, Watanabe T, Mori S, Tajima K. HTLV-I and uveitis. *Lancet*. 1992;339(8801):1110.
  7. Nishioka K, Nakajima T, Hasunuma T, Sato K. Rheumatic manifestation of human leukemia virus infection. *Rheum Dis Clin North Am*. 1993;19(2):489-503.
  8. Gessain A, Jouannelle A, Escarmant P, Calender A, Schaffar-Deshayes L, de-The G. HTLV antibodies in patients with non-Hodgkin lymphomas in Martinique. *Lancet*. 1984;1(8387):1183-4.
  9. Starkebaum G, Loughran TP Jr, Kalyanaraman VS, Kadin ME, Kidd PG, Singer JW, et al. Serum reactivity to human T-cell leukaemia/lymphoma virus type I proteins in patients with large granular lymphocytic leukaemia. *Lancet*. 1987;1(8533):596-9.
  10. Blattner WA, Gibbs WN, Saxinger C, Robert-Guroff M, Clark J, Lofters W, et al. Human T-cell leukaemia/lymphoma virus-associated lymphoreticular neoplasia in Jamaica. *Lancet*. 1983;2(8341):61-4.
  11. Wiktor SZ, Pate EJ, Murphy EL, Palker TJ, Champegnie E, Ramlal A, et al. Mother-to-child transmission of human T-cell lymphotropic virus type I (HTLV-I) in Jamaica: association with antibodies to envelope glycoprotein (gp46) epitopes. *J Acquir Immune Defic Syndr*. 1993;6(10):1162-7.
  12. Okochi K, Sato H, Hinuma Y. A retrospective study on transmission of adult T cell leukemia virus by blood transfusion: seroconversion in recipients. *Vox Sang*. 1984;46(5):245-53.
  13. Donegan E, Lee H, Operskalski EA, Shaw GM, Kleinman SH, Busch MP, et al. Transfusion transmission of retroviruses: human T-lymphotropic virus types I and II compared with human immunodeficiency virus type 1. *Transfusion*. 1994;34(6):478-83.
  14. Kannian P, Green PL. Human T Lymphotropic Virus Type 1 (HTLV-1): Molecular Biology and Oncogenesis. *Viruses*. 2010;2(9):2037-77.
  15. de Montalembert M, Costagliola DG, Lefrere JJ, Cornu G, Lombardo T, Cosentino S, et al. Prevalence of markers for human immunodeficiency virus types 1 and 2, human T-lymphotropic virus type I, cytomegalovirus, and hepatitis B and C virus in multiply transfused thalassemia patients. The French Study Group On Thalassaemia. *Transfusion*. 1992;32(6):509-12.
  16. Covas DT, Boturao Neto E, Zago MA. The frequency of blood-born viral infections in a population of multitransfused Brazilian patients. *Rev Inst Med Trop Sao Paulo*. 1993;35(3):271-3.
  17. Prati D, Capelli C, Rebulla P, Mozzi F, Bosoni P, De Mattei C, et al. The current risk of retroviral infections transmitted by transfusion in patients who have undergone multiple transfusions. CooleyCare Cooperative Group. *Arch Intern Med*. 1998;158(14):1566-9.
  18. Barton EN, King SD, Douglas LL. The seroprevalence of hepatitis and retroviral infection in Jamaican haemodialysis patients. *West Indian Med J*. 1998;47(3):105-7.
  19. Hedayati-Moghaddam M, Fathimoghadam F, Mashhadi IE, Soghandi L, Bidkhori H. Epidemiology of HTLV-1 in Neyshabour, Northeast of Iran. *Iran Red Crescent Med J*. 2011;13(6):424-7.
  20. Azarpazhooh MR, Hasanpour K, Ghanbari M, et al. Human T-lymphotropic virus type 1 prevalence in Northeastern Iran, Sabzevar: an epidemiologic-based study and phylogenetic analysis. *AIDS Res Hum Retroviruses*. 2012;28(9):1095-101.
  21. Bidkhori HR, Hedayati-Moghaddam MR, Fathi-Moghaddam F, Soghandi L, Bakhtiari H, Rezaie AR. High Prevalence of HTLV-1 Infection among Hemodialysis Patients in Neyshabour, Northeast of Iran. *Iran J Allergy Asthma Immunol*. 2013;12(Suppl. 9):38.
  22. Mansouritorghabeh H, Badii Z. Transfusion-Transmitted Viruses in Individuals with  $\beta$  Thalassemia Major at Northeastern Iran, a Retrospective Sero-Epidemiological Survey. *Iran J Blood Cancer*. 2008;1(1):1-4.
  23. Ghaderi A, Habib-Agahi M. High prevalence of anti-HCV and HTLV-1 antibodies in thalassemia major patients of southern Iran. *Iran J Med Sci*. 1996;21(1):60-2.



24. Arjmandi F, Shahriari M, Sadeghi A. Comparison of prevalence of HTLV-1 in patients with leukemia, non-hodgkin lymphoma, thalassemia and blood donors. *J Yazd University Med Sci.* 2002;10(4):25-9. (Article in Persian).
25. Karimi A, Nafisi M. Seroprevalence of Human T-Cell Leukemia Virus Type-1 (HTLV-1) in High Risk Patients. *J Res Health Sci.* 2006;6(2):44-7.
26. Mortezaie Z, Bouzari M, Roghanian R. Evaluating the frequency of HTLV-I/II infection among blood donors, major thalassemic patients and individuals infected with hepatitis B and C viruses in Isfahan, Iran. *Iran J Blood Cancer.* 2012;4(2):169-75.
27. Abedi F, Yavarian M, Shakib zadeh A, Khalvati B, Asadi AH. Seroepidemiology of HTLV in thalassemic, hemophilia and hemodialysis patients in hormozgan province. *J Hormozgan University Med Sci.* 2009;13(2):75-80. (Article in Persian).
28. Anaraki-Mohammadi GR, Sadeghipour AR, Vossough P, Mohammadi IN, Mirnateghi VAM. Assessment of the Prevalence of Human T-Lymphotropic Virus type 1 among Thalassemic Patients with Frequent Blood Transfusion in Tehran in 2003. *J Iran University Med Sci.* 2005;12(47):19-24. (Article in Persian).
29. Ghadiri K, Rezaei M, Payandeh M, Erfan Zare M. Serological Prevalence of Human T-Lymphotropic Virus (HTLV) among major Thalassemic Patients in Kermanshah 2010. *Int J Hematol Oncol Stem Cell Res.* 2011;5(4):51-7.
30. Ghaffari J, Ebrahimi M, Makhloogh A, Mohammadjafari H, Nazari Z. Seroepidemiology of Human T-cell Lymphotropic Virus 1 Infection in Hemodialysis Patients: Should We be Concerned About it? *Iran J Kidney Dis.* 2013;7(3):187-90.
31. Ghaffari J, Kowsarian M, Mahdavi M, Shahi KV, Rafatpanah H, Tafreshian A. Prevalence of HTLV-I Infection in Patients with Thalassemia Major in Mazandaran, North of Iran. *Jundishapur J Microbiol.* 2012;6(1):57-60.
32. Moradi A, Mansurian A, Ahmadi A, Ghaemi E, Kalavi K, Marjani A, et al. Prevalence of HTLV-1 Antibody among Major Thalassemic Patients in Gorgan (South East of Caspian Sea). *J Appl Sci.* 2008;8(2):391-3.
33. Moradi AV, Yaghob Nezhad Z, Mohagheghi AH. Seroepidemiology of HTLV-1 antibody in the thalassemic patients in Zahedan and Zabol cities in 2001. *J Zanzan University Med Sci.* 2003;11(43):43-7. (Article in Persian).
34. Pourkarim MR, Khamisipour GR, Hajiani GRT R, Ardeshtir Davani N. Seroepidemiological investigation of HTLV I/II infection among multi-transfused patients in Bushehr, 2003. *Blood Quart (Sci J Iran Blood Transfus Org).* 2005;2(2):99-103. (Article in Persian).
35. Rezvan H, NourKojory S. Prevalence of HTLV-I/II among Thalasemic and hemophilic patients in Tehran. *Blood Quart (Sci J Iran Blood Transfus Org)* 1995;2(2-3):1-5. (Article in Persian).
36. Rostamzadeh Khameneh Z, Baradaran M, Sepehrvand N. Survey of the seroprevalence of HTLV I/II in hemodialysis patients and blood donors in Urmia. *Saudi J Kidney Dis transpl.* 2008;19(5):838-41.
37. Sotoodeh M, Tabei SZ. Detection of human T-cell leukemia virus carriers in Thalassemia patients in Shiraz: A brief report. *Iran J Med Sci.* 1994;1-2(19):12-4.
38. Ziaee M, Zarban A, Malekinejad P, Akhbary H. Evaluation of HGV viremia prevalence and its co-infection with HBV, HCV, HIV and HTLV-1 in hemophilic patients of Southern Khorassan, Iran. *Hep Mon.* 2007;7(1):11-4.
39. Ardalan N, Abdi M, Zarif BR, Amini A, Meamari F, Haydari E, et al. Prevalence of human T-lymphotropic virus types I & II among high risk groups in Sanandaj in 2010. *Sci J Kurdistan University Med Sci.* 2013;18(2):51-7. (Article in Persian).
40. Hedayati-Moghaddam MR. A Systematic Review for Estimation of HTLV-I Infection in the Blood Donors of Iran. *Iran J Basic Med Sci.* 2013;16(3):196-201.
41. Farid Hossini R, Ghafari J, Miri S, Nasirian A, Rafatpanah H. Seroepidemiology of HTLV-1 in Neishabour. *Med J Mashhad University Med Sci.* 2005;47(4):417-24. (Article in Persian).
42. Lee HH, Galli C, Burczak JD, Biffoni F, De Stasio G, De Virgiliis S, et al. A multicentric seroepidemiological survey of HTLV-I/II in Italy. *Clin Diagn Virol.* 1994;2(3):139-47.
43. Zanetti A, Zehender G, Tanzi E, Galli C, Rezza G, Cargnel A, et al. HTLV-II among Italian intravenous drug users and hemophiliacs. *Eur J Epidemiol.* 1992;8(5):702-7.
44. Nubling M, Nubling CM, Seifried E, Weichert W, Lower J. Human T-cell lymphocytotropic virus prevalence in German blood donors and "at-risk" groups. *Vox Sang.* 2001;81(3):204-6.
45. Naman R, Klayme S, Naboulsi M, Mokhbat J, Jradi O, Ramia S. HTLV-I and HTLV-II infections in volunteer blood donors and high-risk groups in Lebanon. *J Infect.* 2002;45(1):29-31.
46. Regan FA, Hewitt P, Barbara JA, Contreras M.

Dayyani et al.

Prospective investigation of transfusion transmitted infection in recipients of over 20 000 units of blood. TTI Study Group. BMJ. 2000;320(7232):403-6.

47. Mojaat N, Kaabi H, Hmida S, Maamar M, Slama S, Boukef K. Seroprevalence of HTLV-I/II antibodies in blood donors and different groups at risk in Tunisia. J Acquir Immune Defic Syndr. 1999;22(3):314-5.